Company / Capital Expenditures
Larimar Therapeutics, Inc. Capital Expenditures History
FY2014-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$55.0K
FY2019
5-year range
$17.0K / $660.0K
FY2015-FY2019
Trend
-91.7%
vs FY2018
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $595,000 to $55,000 over the past 2 years.
Based on SEC 10-K filings.
$55,000 in FY2019 with a 5-year CAGR of +94.0%.
Declined from $595,000 to $55,000 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -1.8%
- 5-Year CAGR
- +94.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +94.0%, indicating consistent growth.
- In FY2019, capital expenditures decreased 91.7% year-over-year.
- Peak capital expenditures was recorded in FY2018.
- Lowest capital expenditures in the period was in FY2014.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -4.64 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2019 | $55.0K | -91.7% |
| FY2018 | $660.0K | +10.9% |
| FY2017 | $595.0K | +925.9% |
| FY2016 | $58.0K | +241.2% |
| FY2015 | $17.0K | +750.0% |
| FY2014 | $2.0K | - |
As of FY2019 · SEC 10-K · Updated Jun 24, 2026